Inefficacy interim monitoring procedures in randomized clinical trials: The need to report

American Journal of Bioethics

Volumn 11, Issue 3, 2011, Pages 2-10

  Korn, Edward L ^a   Freidlin, Boris ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Clinical research; Data and safety monitoring boards; Early stopping; Futility interim monitoring; Interim analysis; Randomized trial

Indexed keywords

ARTICLE; ECONOMICS; EVIDENCE BASED MEDICINE; HUMAN; METHODOLOGY; PROFESSIONAL STANDARD; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCIBILITY; SAFETY; STANDARD; TIME; TREATMENT OUTCOME;

CLINICAL TRIALS DATA MONITORING COMMITTEES; EVIDENCE-BASED MEDICINE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; SAFETY; TIME FACTORS; TREATMENT OUTCOME;

EID: 79952503735     PISSN: 15265161     EISSN: 15360075     Source Type: Journal    
DOI: 10.1080/15265161.2010.546471     Document Type: Article

References (115)

1. Armstrong, P. W., and C. D. Furberg. 1995. Clinical trial data and safety monitoring boards. Circulation 91: 901-904.
2. DeMets, D. L., S. J. Pocock, and D. G. Julian. 1999. The agonizing negative trend in monitoring of clinical trials. Lancet 354: 1983-1988.
3. DeMets, D. L., and J. H. Ware. 1980. Group sequential methods for clinical trials with a one-sided hypothesis. Biometrika 67: 651-660.
4. Dignam, J. J., J. Bryant, H. S. Wieand, et al. 1998. Early stopping of a clinical trial when there is evidence of no treatment benefit: Protocol B-14 of the National Surgical Adjuvant Breast and Bowel Project. Controlled Clinical Trials 19: 575-588.
5. Ellenberg, S. S., and M. A. Eisenberger. 1985. An efficient design for phase III studies of combination chemotherapies. Cancer Treatment Reports 69: 1147-1152.
6. Ellenberg, S. S., T. R. Fleming, and D. L. DeMets. 2002. Data monitoring committees in clinical trials: A practical perspective. Chichester, England: JohnWiley.
7. Freidlin, B., and E. L. Korn. 2002. Acomment on futility monitoring. Controlled Clinical Trials 23: 355-366.
8. Freidlin, B., and E. L. Korn. 2009. Monitoring for lack of benefit: A critical component of a randomized clinical trial. Journal of Clinical Oncology 27: 629-633.
9. Freidlin, B., E. L. Korn, and R. Gray. 2010. A general inefficacy interimmonitoring rule for randomized clinical trials. Clinical Trials 7: 197-208.
10. Freidlin, B., L. M. McShane, and E. L. Korn. 2010. Randomized clinical trials with biomarkers: design issues. Journal of the National Cancer Institute 102: 152-160.
11. Friedman, L.M., C. D. Furberg, and D. L. DeMets. 1998. Fundamentals of clinical trials, 3rd ed. New York: Springer.
12. Green, S. J., T. R. Fleming, and J. R. O'Fallon. 1987. Policies for study monitoring and interim reporting of results. Statistics in Medicine 5: 1477-1484.
13. Jennison, C., and B.W. Turnbull. 2000. Group sequential methods with applications to clinical trials. Boca Raton, FL: Chapman & Hall/CRC.
14. Korn, E. L., and B. Freidlin. 2010. Interim analysis of phase III clinical trials. In Oncology clinical trials: Successful design, conduct, and analysis, ed. W. K. Kelly, and S. Halabi, 163-177. New York: Demos Medical Publishing.
15. Lan, K. K. G., R. Simon, and M. Halperin. 1982. Stochastically curtailed tests in long-term clinical trials. Communications in Statistics Series C 1: 207-219.
16. Meinert, C. L. 1998. Masked monitoring in clinical trials-Blind stupidity? New England Journal of Medicine 338: 1381-1382.
17. Nelson, H., D. J. Sargent, H. S. Weiand, et al. 2004. A comparison of laparoscopically assisted and open colectomy for colon cancer. New England Journal of Medicine 350: 2050-2059.
18. NICE-SUGAR Study Investigators. 2009. Intensive versus conventional glucose control in critically ill patients. New England Journal of Medicine 360: 1283-1297.
19. Pampallona, S., and A. A. Tsiatis. 1994. Group sequential designs for one-sided and two-sided hypothesis testing with provision for early stopping in favor of the null hypothesis. Journal of Statistical Planning and Inference 42: 19-35.
20. Pocock, S. J. 1992. When to stop a clinical trial. British Medical Journal 305: 235-240.
21. Schulz, K. F., D. G. Altman, D. Moher, for the CONSORT Group. 2010. CONSORT 2010 statement: Updated guidelines for reporting parallel group randomized trials. Annals of Internal Medicine 152: 726-733.
22. Tol, J., M. Koopman, A. Cats, et al. 2009. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. New England Journal of Medicine 360: 563-572.
23. Ware, J. H., J. E. Muller, and E. Braunwald. 1985. The futility index. American Journal of Medicine 78: 635-643.
24. Wieand, S., G. Schroeder, and J. R. O'Fallon. 1994. Stopping when the experimental regimen does not appear to help. Statistics in Medicine 13: 1453-1458.
25. Wittes, J. 2004. Forming your phase III trial's data and safety monitoring board: A perspective on safety. Journal of Investigative Medicine 52: 453-458.
26. Arts, M. P., R. Brand, M. E. Van Den Akker, et al. 2009. Tubular diskectomy vs conventional microdiskectomy for sciatica: A randomized controlled trial. Journal of the American Medical Association 302: 149-158.
27. ASTRAL Investigators. 2009. Revascularization versus medical therapy for renal-artery stenosis. New England Journal of Medicine 361: 1952-1962.
28. Coulibaly, Y. I., B. Dembele, A. A. Diallo, et al. 2009. A randomized trial of doxycycline for Mansonella perstans infection. New England Journal of Medicine 361: 1448-1458.
29. Cummings, S. R., J. San Martin, M. R. McClung, et al. 2009. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. New England Journal of Medicine 361: 756-765.
30. Hurst, L. C., M. A. Badalamente, V. R. Hentz, et al. 2009. Injectable collagenase clostridium histolyticum for Dupuytren's contracture. New England Journal of Medicine 361: 968-979.
31. Kroenke, K., M. Bair, T. Damush, et al. 2007. Stepped Care for Affective Disorders and Musculoskeletal Pain (SCAMP) study design and practical implications of an intervention for comorbid pain and depression. General Hospital Psychiatry 29(6): 506-517. [trial-design paper]
32. Kroenke, K., M. J. Bair, T. M. Damush, et al. 2009. Optimized antidepressant therapy and pain self-management in primary care patients with depression and musculoskeletal pain: A randomized controlled trial. Journal of the American Medical Association 301: 2099-110.
33. Lederle, F. A., J. A. Freischlag, T. C. Kyriakides, et al. 2009. Open Versus Endovascular Repair (OVER) Veterans Affairs Cooperative Study Group. Outcomes following endovascular vs open repair of abdominal aortic aneurysm: a randomized trial. Journal of the American Medical Association 302: 1535-1542
34. Meuwese, M. C., E. de Groot, R. Duivenvoorden, et al. 2009. ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia. The CAPTIVATE randomized trial. Journal of the American Medical Association 301: 1131-1139.
35. Shaheen, N. J., P. Sharma, B. F. Overholt, et al. 2009. Radiofrequency ablation in Barrett's esophagus with dysplasia. New England Journal of Medicine 360: 2277-2288.
36. Tonino, P. A. L., B. De Bruyne, N. H. J. Pijls, et al. 2009. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. New England Journal of Medicine 360: 213-224.
37. van Gils, E. J. M., R. H. Veenhoven, E. Hak, et al. 2009. Effect of reduced-dose schedules with 7-valent pneumococcal conjugate vaccine on nasopharyngeal pneumococcal carriage in children: A randomized controlled trial. Journal of the American Medical Association. 302(2): 159-167.
38. Cantor, W. J., D. Fitchett, B. Borgundvaag, et al. 2009. Routine early angioplasty after fibrinolysis for acute myocardial infarction. New England Journal of Medicine 360: 2705-2718.
39. Cantor, W. J., D. Fitchett, B. Borgundvaag, et al. 2008. Rationale and design of the Trial of Routine ANgioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI). American Heart Journal 155: 19-25. (trial-design paper)
40. Disertori, M., R. Latini, A. P. Maggioni, et al. 2006. Rationale and design of the GISSI-Atrial Fibrillation Trial:Arandomized, prospective, multicenter study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence. Journal of Cardiovascular Medicine 7: 29-38. (trial-design paper)
41. Ducharme, F. M., C. Lemire, F. J. D. Noya, et al. 2009. Preemptive use of high-dose fluticasone for virus-induced wheezing in young children. New England Journal of Medicine 360: 339-353.
42. GISSI-AF Investigators. 2009. Valsartan for prevention of recurrent atrial fibrillation. New England Journal of Medicine 360: 1606-1617.
43. Mehran, R., B. Brodie, D. A. Cox, et al. 2008. The Harmonizing Outcomes with Revasculari ZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI)Trial: Study design and rationale. American Heart Journal 156: 44-56. [trial-design paper]
44. Moers, C., J. M. Smits, M.-H. J. Maathuis, et al. 2009. Machine perfusion or cold storage in deceased-donor kidney transplantation. New England Journal of Medicine 360: 7-19.
45. Oviedo-Joekes, E., S. Brissette, D. C. Marsh, et al. 2009. Diacetylmorphine versus methadone for the treatment of opioid addiction. New England Journal of Medicine 361: 777-786.
46. Panickar, J., M. Lakhanpaul, P. C. Lambert, et al. 2009. Oral prednisolone for preschool childrenwith acute virus-induced wheezing. New England Journal of Medicine 360: 329-338.
47. Stone, G.W., A. J. Lansky, S. J. Pocock, et al. 2009. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. New England Journal of Medicine 360: 1946-1959.
48. American Lung Association Asthma Clinical Research Centers. 2009. Efficacy of esomeprazole for treatment of poorly controlled asthma. New England Journal of Medicine 360: 1487-1499.
49. Anker, S. D., J. C. Colet, G. Filippatos, et al. 2009. Rationale and design of Ferinject Assessment in patient with IRon deficiency and chronic Heart Failure (FAIR-HF) study: A randomised, placebo controlled study of intravenous iron supplementation in patients with and without anaemia. European Journal of Heart Failure 11: 1084-1091. [trial-design paper]
50. Anker, S. D., J. Comin Colet, G. Filippatos, et al. 2009. Ferric carboxymaltose in patients with heart failure and iron deficiency. New England Journal of Medicine 361: 2436-2448.
51. Azzopardi, D. V., B. Strohm, A. D. Edwards, et al. 2009. Moderate hypothermia to treat perinatal asphyxial encephalopathy. New England Journal of Medicine 361: 1349-1358.
52. Buchbinder, R., R. H. Osborne, P. R. Ebeling, et al. 2009. A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures. New England Journal of Medicine 361: 557-568.
53. Cohen, A. S., B. Burns, and P. J. Goadsby. 2009. High-flow oxygen for treatment of cluster headache: A randomized trial. Journal of the American Medical Association 302: 2451-2457.
54. Craig, J. C., J. M. Simpson, G. J. Williams, et al. 2009. Antibiotic prophylaxis and recurrent urinary tract infection in children. New England Journal of Medicine 361: 1748-1759.
55. Fung, J. W., J. Y. Chan, R. Omar, et al. 2007. The Pacing to Avoid Cardiac Enlargement (PACE) trial: Clinical background, rationale, design, and implementation. Journal of Cardiovasccular Electrophysiology 18: 735-739. [trial-design paper]
56. Green, R. C., L. S. Schneider, D. A. Amato, et al., 2009. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: A randomized controlled trial. Journal of the American Medical Association 302: 2557-2564.
57. Lenze, E. J., B. L. Rollman, M. K. Shear, et al. 2009. Escitalopram for older adults with generalized anxiety disorder: A randomized controlled trial. Journal of the American Medical Association 301: 295-303.
58. Löwenberg, B., G. J. Ossenkoppele, W. van Putten, et al. 2009. High-dose daunorubicin in older patients with acute myeloid leukemia. New England Journal of Medicine 361: 1235-1248.
59. Mauer, M., B. Zinman, R. Gardiner, et al. 2002. ACE-I and ARBs in early diabetic nephropathy. Journal of Renin, Angiotensin and Aldosterone Systems 3: 262-269. [trial-design paper]
60. Mauer, M., B. Zinman, R. Gardiner, et al. 2009. Renal and retinal effects of enalapril and losartan in type 1 diabetes. New England Journal of Medicine 361: 40-51.
61. McHutchison, J. G., E. J. Lawitz, M. L. Shiffman, et al. 2009. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. New England Journal of Medicine 361: 580-593.
62. Mehta, S. R., C. B. Granger, W. E. Boden, et al. 2009. Early versus delayed invasive intervention in acute coronary syndromes. New England Journal of Medicine 360: 2165-2175.
63. Montalescot, G., G. Cayla, J. P. Collet, et al. 2009. Immediate vs delayed intervention for acute coronary syndromes: A randomized clinical trial. Journal of the American Medical Association 302: 947-954.
64. Morin, C. M., A. Vallieres, B. Guay, et al. 2009. Cognitive behavioral therapy, singly and combined with medication, for persistent insomnia: A randomized controlled trial. Journal of the American Medical Association 301: 2005-2015.
65. Schouten, O., E. Boersma, S. E. Hoeks, et al. 2009. Fluvastatin and perioperative events in patients undergoing vascular surgery. New England Journal of Medicine 361: 980-989.
66. Schnuelle, P., U. Gottmann, S. Hoeger, et al. 2009. Effects of donor pretreatment with dopamine on graft function after kidney transplantation: A randomized controlled trial. Journal of the American Medical Association. 302: 1067-1075.
67. Tol, J., M. Koopman, A. Cats, et al. 2009. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. New England Journal of Medicine 360: 563-572.
68. Tol, J., M. Koopman, C. J. Rodenburg, et al. 2008. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG): An interim analysis of toxicity. Annals of Oncology 19: 734-738. [trialdesign paper]
69. Van Cutsem, E., C.-H. Köhne, E. Hitre, et al. 2009. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. New England Journal of Medicine 360: 1408-1417.
70. Weaver, F. M., K. Follett, M. Stern, et al. 2009. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: A randomized controlled trial. Journal of the American Medical Association 301: 63-73.
71. Yu, C.-M., J. Y.-S. Chan, Q. Zhang, et al. 2009. Biventricular pacing in patients with bradycardia and normal ejection fraction. New England Journal of Medicine 361: 2123-2134.
72. ACTIVE Investigators. 2009. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. New England Journal of Medicine 360: 2066-2078.
73. Connolly, S. J., S. Yusuf, A. Budaj, et al. 2006. Rationale and design of ACTIVE: The Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events. American Heart Journal 151: 1187-1193. [trial-design paper]
74. Brunner-La Rocca, H. P., P. T. Buser, and R. Schindler. 2006. Management of elderly patientswith congestive heart failure-design of the Trial of Intensified Versus Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF). American Heart Journal. 15: 949-955. [trial-design paper]
75. Dixon, B. S., G. J. Beck, M. A. Vazquez, et al. 2009. Effect of dipyridamole plus aspirin on hemodialysis-graft patency. New England Journal of Medicine 360: 2191-2201.
76. ESCAPE Trial Group. 2009. Strict blood-pressure control and progression of renal failure in children. New England Journal of Medicine 361: 1639-1650.
77. Fellström, B. C., A. G. Jardine, R. E. Schmieder, et al. 2009. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. New England Journal of Medicine 360: 1395-1407.
78. Fellström, B., F. Zannad, R. Schmieder, et al. 2005. Effect of rosuvastatin on outcomes in chronic haemodialysis patients-Design and rationale of the AURORA study. Current Controlled Trials in Cardiovascular Medicine 6: article 9. [trial-design paper]
79. Finfer, S., A. Cass, M. Gallagher, et al. 2009. The RENAL (Randomized Evaluation of Normal vs. Augmented Level Replacement Therapy) study: Statistical analysis plan. Critical Care and Resuscitation 11: 58-66. [trial-design paper]
80. Jones, R. H., E. J. Velazquez, R. E. Michler, et al. 2009. Coronary bypass surgerywith or without surgical ventricular reconstruction. New England Journal of Medicine 360: 1705-1717.
81. Kallmes, D. F., B. A. Comstock, P. J. Heagerty, et al. 2009. A randomized trial of vertebroplasty for osteoporotic spinal fractures. New England Journal of Medicine 361: 569-579.
82. Moss, A. J., W. J. Hall, D. S. Cannom, et al. 2009. Cardiacresynchronization therapy for the prevention of heart-failure events. New England Journal of Medicine 361: 1329-1338.
83. NICE-SUGAR Study Investigators. 2009. Intensive versus conventional glucose control in critically ill patients. New England Journal of Medicine 360: 1283-1297.
84. Pfisterer, M. P., P. Buser, H. Rickli, et al. 2009. BNP-guided vs symptom-guided heart failure therapy: The Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. Journal of the American Medical Association 301(4): 383-392.
85. RENAL Replacement Therapy Study Investigators. 2009. Intensity of continuous renal-replacement therapy in critically ill patients. New England Journal of Medicine 361: 1627-1638.
86. Taylor, A. J., T. C. Villines, E. J. Stanek, et al. 2009. Extended-release niacin or ezetimibe and carotid intima-media thickness. New England Journal of Medicine 361: 2113-2122.
87. Velazquez, E. J., K. L. Lee, C. M. O'Connor, et al. 2007. The rationale and design of the Surgical Treatment for Ischemic Heart Failure (STICH) trial. Journal of Thoracic and Cardiovascular Surgery 134: 1540-1547. (trial-design paper)
88. Bhatt, D. L., A. M. Lincoff, C. M. Gibson, et al. 2009. Intravenous platelet blockade with cangrelor during PCI. New England Journal of Medicine 361: 2330-2341.
89. Fernandez, H. F., Z. Sun, X. Yao, et al. 2009. Anthracycline dose intensification in acute myeloid leukemia. New England Journal of Medicine 361: 1249-1259.
90. Harrington, R. A., G. W. Stone, S. McNulty, et al. 2009. Platelet inhibition with cangrelor in patients undergoing PCI. New England Journal of Medicine 361: 2318-2329.
91. INSIGHT-ESPRIT Study Group, SILCAAT Scientific Committee. 2009. Interleukin-2 therapy in patients with HIV infection. New England Journal of Medicine 361: 1548-1559.
92. Meyhoff, C. S., J. Wetterslev, L. N. Jorgensen, et al. 2009. Effect of high perioperative oxygen fraction on surgical site infection and pulmonary complications after abdominal surgery: The PROXI randomized clinical trial. Journal of the American Medical Association 302: 1543-1550.
93. Meyhoff, C. S., J. Wetterslev, L. N. Jorgensen, et al. 2008. Perioperative oxygen fraction-Effect on surgical site infection and pulmonary complications after abdominal surgery: A randomized clinical trial: rationale and design of the PROXI trial. Trials 9: 58 [trial-design paper]
94. Pfeffer, M. A., E. A. Burdmann, C.-Y. Chen, et al. 2009. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. New England Journal of Medicine 361: 2019-2032.
95. Pradhan, A. D., B. M. Everett, N. R. Cook, et al. 2009. Effects of initiating insulin andmetformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: The LANCET randomized trial. Journal of the American Medical Association 302: 1186-1194.
96. Rerks-Ngarm, S., P. Pitisuttithum, S. Nitayaphan, et al. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. New England Journal of Medicine 361: 2209-2220.
97. Duckworth, W., C. Abraira, T. Moritz, et al. 2009. Glucose control and vascular complications in veterans with type 2 diabetes. New England Journal of Medicine 360: 129-139.
98. Giugliano, R. P., J. A. White, C. Bode, et al. 2009. Early versus delayed, provisional eptifibatide in acute coronary syndromes. New England Journal of Medicine 360: 2176-2190.
99. INSIGHT-ESPRIT Study Group, SILCAAT Scientific Committee. 2009. Interleukin-2 therapy in patients with HIV infection. New England Journal of Medicine 361: 1548-1559.
100. James, S., A. Akerblom, C. P. Cannon, et al. 2009. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. American Heart Journal 157: 599-605. [trial-design paper]
101. Landon, M. B., C. Y. Spong, E. Thom, et al. 2009. A multicenter, randomized trial of treatment for mild gestational diabetes. New England Journal of Medicine 361: 1339-1348.
102. Plint, A. C., D. W. Johnson, H. Patel, et al. 2009. Epinephrine and dexamethasone in children with bronchiolitis. New England Journal of Medicine 360: 2079-2089.
103. Smith, M. R., B. Egerdie, N. Herńandez Toriz, et al. 2009. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. New England Journal of Medicine 361: 745-755.
104. Slaughter, M. S., J. G. Rogers, C. A. Milano, et al. 2009. Advanced heart failure treated with continuous-flow left ventricular assist device. New England Journal of Medicine 361: 2241-2251.
105. Steinbeck, G., D. Andresen, K. Seidl, et al. 2009. Defibrillator implantation early after myocardial infarction. New England Journal of Medicine 361: 1427-1436.
106. Wallentin, L., R. C. Becker, A. Budaj, et al. 2009. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. New England Journal of Medicine 361: 1045-1057.
107. BARI 2D Study Group. 2009. A randomized trial of therapies for type 2 diabetes and coronary artery disease. New England Journal of Medicine 360: 2503-2515.
108. Brooks, M. M., R. L. Frye, S. Genuth, et al. 2006. Hypotheses, design, and methods for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. American Journal of Cardiology 97(suppl. 12A): 9G-19G. [trial-design paper]
109. Daniels, J., R. Gray, R. K. Hills, et al. 2009. Laparoscopic uterosacral nerve ablation for alleviating chronic pelvic pain: A randomized controlled trial. Journal of the American Medical Association 302: 955-961.
110. Fischer, B., U. Lassen, J. Mortensen, et al. 2009. Preoperative staging of lung cancer with combined PET-CT. New England Journal of Medicine 361: 32-39.
111. Gnant, M., B, Mlineritsch, W. Schippinger, et al. 2009. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. New England Journal of Medicine 360: 679-691.
112. Hohnloser, S.H., H. J. G. M. Crijns, M. van Eickels, et al. 2009. Effect of dronedarone on cardiovascular events in atrial fibrillation. New England Journal of Medicine 360: 668-678.
113. Latthe, P., K. S. Khan, J. K. Gupta, et al. 2003. A randomised controlled trial to assess the efficacy of laparoscopic uterosacral nerve ablation (LUNA) in the treatment of chronic pelvic pain: The trial protocol [ISRCTN41196151]. BiMCWomen'sHealth 3: 6. [trial-design paper]
114. Olasveengen, T. M., K. Sunde, C. Brunborg, et al. 2009. Intravenous drug administration during out-of-hospital cardiac arrest: A randomized trial. Journal of the American Medical Association 302: 2222-2229.
115. Taccone, P., A. Pesenti, R. Latini, et al. 2009. Prone positioning in patients with moderate and severe acute respiratory distress syndrome: A randomized controlled trial. Journal of the American Medical Association 302: 1977-1984.